CN117264812A - 一株融合魏斯氏菌及其在制备降脂产品中的应用 - Google Patents
一株融合魏斯氏菌及其在制备降脂产品中的应用 Download PDFInfo
- Publication number
- CN117264812A CN117264812A CN202311096261.3A CN202311096261A CN117264812A CN 117264812 A CN117264812 A CN 117264812A CN 202311096261 A CN202311096261 A CN 202311096261A CN 117264812 A CN117264812 A CN 117264812A
- Authority
- CN
- China
- Prior art keywords
- weissella
- fusion
- cgmcc
- confusa
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000004927 fusion Effects 0.000 claims abstract description 45
- 241000202221 Weissella Species 0.000 claims abstract description 44
- 241000186675 Weissella confusa Species 0.000 claims abstract description 29
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 18
- 239000002158 endotoxin Substances 0.000 claims abstract description 18
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000002068 microbial inoculum Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 239000006872 mrs medium Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 abstract description 35
- 150000002632 lipids Chemical class 0.000 abstract description 10
- 238000004220 aggregation Methods 0.000 abstract description 9
- 239000006041 probiotic Substances 0.000 abstract description 8
- 235000018291 probiotics Nutrition 0.000 abstract description 8
- 239000002253 acid Substances 0.000 abstract description 7
- 239000003833 bile salt Substances 0.000 abstract description 7
- 230000000529 probiotic effect Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 2
- 241000699800 Cricetinae Species 0.000 description 43
- 230000000694 effects Effects 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 235000019577 caloric intake Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010059866 Drug resistance Diseases 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
- 102000000018 Chemokine CCL2 Human genes 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011553 hamster model Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 101710150365 Albumin-1 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- -1 cephem compounds Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及微生物技术领域,具体涉及一株融合魏斯氏菌及其在制备降脂产品中的应用。本发明提供的融合魏斯氏菌(Weissella confusa)Wc1982保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.27139。融合魏斯氏菌(Weissella confusa)CGMCC No.27139具有较强的耐酸、耐胆盐能力,具有较高的自聚集能力和疏水性,能够降低血清脂质水平,并降低血清炎症因子和内毒素水平,可作为益生菌制剂用于预防和缓解高脂血症,为高脂血症的防治提供了新的策略,具有潜在的临床应用前景。
Description
技术领域
本发明涉及微生物技术领域,尤其涉及一株融合魏斯氏菌及其在制备降脂产品中的应用。
背景技术
高脂血症是一种以血清中的总胆固醇、甘油三酯、低密度脂蛋白胆固醇浓度升高和/或高密度脂蛋白胆固醇浓度降低为主要特征的全身性脂质代谢紊乱疾病。血脂异常与心血管疾病的发生、发展及死亡过程密切相关,是心血管疾病的主要危险因素。控制血脂已经成为防治心血管疾病的重要措施,有研究发现血清总胆固醇浓度降低1%可使冠状动脉疾病的危险性降低2-3%。但考虑到药物治疗的成本及潜在的副作用,亟需补充与替代疗法。研究表明益生菌具有改善血脂代谢的功效,其在降脂方面的应用受到越来越多的关注。
融合魏斯氏菌(Weissella confusa)通常分离自植物和发酵食品中,在人和动物的肠道也能定植。此外,在健康女性的母乳中也分离到了融合魏斯氏菌。目前该菌被认为是可以直接食用的候选益生菌。近年来,已报道该菌具有抗菌和抗炎功能,但对于其体内降脂功效暂无报道。
发明内容
本发明提供一株融合魏斯氏菌及其在制备降脂产品中的应用。
本发明提供融合魏斯氏菌(Weissella confusa)Wc1982,该菌株于2023年4月17日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编100101),分类命名为融合魏斯氏菌Weissella confusa,保藏编号为CGMCC No.27139。
融合魏斯氏菌(Weissella confusa)CGMCC No.27139从健康人粪便样本中分离得到,对机体相对安全,有较强的耐酸和耐胆盐能力,以及较高的自聚集能力和表面疏水性。经动物实验验证,该菌株具有降低血脂的功效,还具有降低血清炎症因子和内毒素的功能,适用于作为益生菌制剂防治高脂血症。此外,该菌株对于脂代谢紊乱导致的肝脏疾病也具有改善作用。
本发明提供一种菌剂,所述菌剂包含以上所述的融合魏斯氏菌(Weissellaconfusa)CGMCC No.27139。
优选地,所述菌剂中融合魏斯氏菌(Weissella confusa)CGMCCNo.27139以活菌形式存在。
所述菌剂可以为液体菌剂或固体菌剂。
本发明提供所述菌剂的制备方法,所述方法包括培养所述融合魏斯氏菌(Weissella confusa)CGMCC No.27139的步骤。
优选地,所述培养使用的培养基为MRS培养基。
优选地,所述培养在35-37℃条件下进行。
经培养获得的融合魏斯氏菌(Weissella confusa)CGMCCNo.27139的菌液可直接或加入微生物制剂领域允许的辅料制备为液体菌剂,也可收集菌液中的菌体与冻干保护剂等微生物制剂领域允许的辅料混合后经真空冷冻干燥制备为干粉菌剂。
基于融合魏斯氏菌(Weissella confusa)CGMCC No.27139的功能,本发明提供该菌株的以下应用:
本发明提供所述融合魏斯氏菌(Weissella confusa)CGMCCNo.27139或所述菌剂在制备食品或药物中的应用。
本发明提供所述融合魏斯氏菌(Weissella confusa)CGMCCNo.27139或所述菌剂在制备用于预防、改善或治疗高脂血症的产品中的应用。
优选地,所述预防、改善或治疗高脂血症为降低血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇和/或升高高密度脂蛋白胆固醇。
本发明提供所述融合魏斯氏菌(Weissella confusa)CGMCCNo.27139或所述菌剂在制备用于降低炎症因子和/或内毒素水平的产品中的应用。
优选地,所述降低炎症因子和/或内毒素为降低高脂血症中血清炎症因子和/或内毒素。
其中,所述炎症因子包括白介素-1β、白介素-6、肿瘤坏死因子-α和单核细胞趋化蛋白-1。
本发明提供所述融合魏斯氏菌(Weissella confusa)CGMCCNo.27139或所述菌剂在制备用于预防、缓解或治疗因脂代谢紊乱导致的肝脏疾病的产品中的应用。
优选地,所述肝脏疾病包括肝功能障碍、脂肪肝等。
上述应用中,所述产品为食品或药物。其中所述食品为普通食品或保健品。
优选地,所述产品为胶囊、冻干粉或者菌液制剂。
本发明提供一种产品,所述产品包含以上所述的融合魏斯氏菌(Weissellaconfusa)CGMCC No.27139或所述菌剂,或者,所述产品由所述融合魏斯氏菌(Weissellaconfusa)CGMCC No.27139制备得到。
优选地,所述产品为食品或药物。其中所述食品为普通食品或保健品。
优选地,所述产品为胶囊、冻干粉或者菌液制剂。
本发明的有益效果至少包括:本发明提供的融合魏斯氏菌(Weissella confusa)CGMCC No.27139具有较强的耐酸、耐胆盐能力,能够耐受胃肠道环境;同时该菌株自聚集能力和表面疏水性较高,具有在肠道中粘附定植的潜力。通过高脂血症仓鼠模型验证,该菌株可降低血清脂质、炎症因子和内毒素的水平,缓解肝脏脂肪变性,且对实验动物无明显毒副作用。该菌株降脂功效显著,可作为益生菌制剂用于防治高脂血症,为高脂血症的防治提供了新的策略;在药品、食品以及多种形式的益生菌产品中具有广泛的应用价值,具有潜在的临床应用前景。
附图说明
为了更清楚地说明本发明或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作一简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明实施例3中融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的体重和能量摄入量的影响,其中,A为体重变化,B为总能量摄入。
图2为本发明实施例3中融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的血脂水平的影响,其中,A为血清总胆固醇浓度,B为血清甘油三酯浓度,C为血清低密度脂蛋白胆固醇浓度,D为血清高密度脂蛋白胆固醇浓度。
图3为本发明实施例3中融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的血清炎症因子和内毒素水平的影响,其中,A为血清白介素-1β浓度,B为血清白介素-6浓度,C为血清肿瘤坏死因子-α浓度,D为血清单核细胞趋化蛋白-1浓度,E为血清内毒素浓度。
图4为本发明实施例3中融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的血清谷丙转氨酶和谷草转氨酶水平的影响,其中,A为血清谷丙转氨酶浓度,B为血清谷草转氨酶浓度。
图5为本发明实施例3中融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的肝脏组织病理的影响,图中所示为肝脏组织H&E染色病理切片镜下图(标尺:1000μm;100μm),实心箭头指示泡沫状微小脂滴,线型箭头指示气球样变性,开叉箭头指示淋巴细胞浸润。
图1-5中,NC代表正常对照组,HFD代表高脂模型组,Wc1982代表融合魏斯氏菌CGMCC No.27139干预组。以x±SD展示结果,N=8;*:P<0.05;**:P<0.01;***:P<0.001。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合本发明中的附图,对本发明中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1菌株的分离和鉴定
1、菌株分离
取适量冻存于-80℃冰箱中的健康人粪便样本置于冰上缓慢解冻,用PBS梯度稀释后,移取不同稀释度的样品悬浮液100μL至MRS培养基,均匀涂布,置于37℃、需氧条件下培养48h,挑取不同形态特征的菌落进行传代纯化,连续转接3次,纯化菌株可用于实验或冷冻保藏。
本发明自健康人粪便样本中分离得到一株融合魏斯氏菌(命名为Wc1982),并对该菌株进行抗生素敏感性和耐受性评价以及粘附相关实验,结果显示该菌株除对万古霉素固有耐药外对所测抗生素均敏感,耐酸和耐胆盐性能良好,且具有较高的自聚集能力和表面疏水性,随后将融合魏斯氏菌Wc1982进行体内降脂功效测试(所有实验方法参考实施例2-3)。
2、菌种保藏
以含25%甘油的培养基作为保菌液进行菌种的冷冻保藏,方法如下:将容量为2mL的保菌管中加入1.5mL保菌液,经121℃,15min高压灭菌处理后以备使用;菌株在MRS固体培养基上连续转接3次后,用无菌接种环刮取菌体至保菌管中并充分融入保菌液,混匀后于-80℃冻存。
3、菌株16S rRNA基因鉴定
使用Genomic DNA纯化试剂盒提取该分离菌株基因组DNA,用16S rRNA基因通用引物(27F:AGAGTTTGATCCTGGCTCA;1492R:AAGTCGTAACAAGGTAGCCGT)扩增菌株16SrRNA基因,对PCR扩增产物进行测序,将测序所得序列在NCBI在线数据库进行BLAST比对。PCR反应的条件和PCR体系(30μL)的组成如下:
PCR反应体系(30μL):Premix Taq,15μL;ddH2O,12μL;上下游引物,各1μL;基因组DNA,1μL。
PCR扩增条件:94℃预变性,5min;94℃变性、0.5min,55℃退火、0.5min,72℃延伸、0.5min,30个循环;72℃终延伸,1min。
测序结果显示,待测菌株16S rRNA基因序列(SEQ ID NO.1)为:GCAGTCGACGCTTTGTGGTTCAACTGATTTGAAGAGCTTGC TCAGATATGACGATGGACATTGCAAAGAGTGGCGAACGGGTGAGTAACACGTGGGAAACCTACCTCTTAGCAGGGGATAACATTTGGAAACAGATGCTAATACCGTATAACAATGACAACCGCATGGTTGTTATTTAAAAGATGGTTCTGCTATCACTAAGAGATGGTCCCGCGGTGCATTAGCTAGTTGGTAAGGTAATGGCTTACCAAGGCGATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACAATGGGACTGAGACACGGCCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGGCGAAAGCCTGATGGAGCAACGCCGCGTGTGTGATGAAGGGTTTCGGCTCGTAAAACACTGTTGTAAGAGAAGAATGACATTGAGAGTAACTGTTCAATGTGTGACGGTATCTTACCAGAAAGGAACGGCTAAATACGTGCCAGCAGCCGCGGTAATACGTATGTTCCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGACGGTTATTTAAGTCTGAAGTGAAAGCCCTCAGCTCAACTGAGGAATTGCTTTGGAAACTGGATGACTTGAGTGCAGTAGAGGAAAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTTTCTGGACTGTAACTGACGTTGAGGCTCGAAAGTGTGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCACACCGTAAACGATGAGTGCTAGGTGTTTGAGGGTTTCCGCCCTTAAGTGCCGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCCTTGACAACTCCAGAGATGGAGCGTTCCCTTCGGGGACAAGGTGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTACTAGTTGCCAGCATTCAGTTGGGCACTCTAGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGCGTATACAACGAGTTGCCAACCCGCGAGGGTGAGCTAATCTCTTAAAGTACGTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCAAAGCCGGTGGGGTAACCTTCGGGAGCCAGCCGTCTA。
待测菌株序列比对结果显示,待测菌株Wc1982与融合魏斯氏菌模式株JCM 1093的序列一致性为99.93%,超过种间阈值98.75%,因此判定该分离菌株为融合魏斯氏菌。
融合魏斯氏菌(Weissella confusa)Wc1982已于2023年4月17日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编100101),分类命名为融合魏斯氏菌Weissellaconfusa,保藏编号为CGMCC No.27139。
实施例2融合魏斯氏菌CGMCC No.27139的特性分析
1、融合魏斯氏菌CGMCC No.27139的抗生素敏感性检测依据临床和实验室标准协会(CLSI)M45标准,选择青霉素类:青霉素、氨苄西林;四环素类:四环素;氯霉素类:氯霉素;头孢烯类:头孢曲松;糖肽类:万古霉素;恶唑烷酮类:利奈唑胺;青霉烯类:美罗培南;喹诺酮类:左氧氟沙星;大环内酯类:红霉素;林可酰胺类:克林霉素进行抗生素敏感性实验。肺炎链球菌(Streptococcus pneumoniae)ATCC 49619作为质量控制菌株(QC),采用抗生素浓度梯度法(E-test法),读取其最小抑制浓度(MIC)值。
结果如表1所示,融合魏斯氏菌CGMCC No.27139除对万古霉素固有耐药外,对其余10种选用的抗生素均敏感,安全性较高。固有耐药是指细菌对某种抗菌药物的天然耐药性,由固有耐药基因决定;固有耐药基因是存在于细菌染色体上位置保守、且与耐药相关的一类基因。研究表明许多乳酸菌,包括魏斯氏菌属,对万古霉素存在固有耐药性。
表1融合魏斯氏菌CGMCC No.27139的抗生素敏感性结果
注:S代表敏感,R代表耐药,QC代表质量控制菌株。
2、融合魏斯氏菌CGMCC No.27139对酸和胆盐的耐受性
待活化三代的融合魏斯氏菌CGMCC No.27139生长饱和后,将浓度为1×108CFU/mL的菌液以10%接种量接种于pH=3.0的MRS液体培养基或含有0.3%胆盐的MRS液体培养基中,在37℃环境中培养3h或4h;将菌悬液梯度稀释,每个梯度取10μL滴种于MRS固体培养基上,37℃、5% CO2条件下培养24h后,计数其存活细菌量并计算存活率。存活率(%)=(lgCFU N1/lg CFU N0)×100%,N1为培养后计数所得菌量,N0为初始菌量。
通过模拟人体胃肠道环境考察菌株在pH=3.0和含0.3%胆盐的MRS培养基中的存活情况,来评价菌株对胃肠道的耐受能力。结果如表2所示,融合魏斯氏菌CGMCC No.27139具有较强的耐酸和耐胆盐能力。
表2融合魏斯氏菌CGMCC No.27139的耐酸、耐胆盐情况
注:*LGG为商用益生菌鼠李唐乳杆菌GG(ATCC 53103),作为阳性对照。
3、融合魏斯氏菌CGMCC No.27139的自聚集能力和疏水性
自聚集能力评价:将生长至饱和的融合魏斯氏菌CGMCCNO.27139悬浮于PBS中,调节其麦氏浊度为1.0(OD0),将菌悬液于37℃培养24h后,测定其浊度(OD1)。
疏水性实验:在用0.85% NaCl溶液调节至麦氏浊度1.0(OD0)的2mL菌悬液中加入2mL的二甲苯,涡旋混匀2min后于37℃中孵育1h,弃去有机溶剂层,测定其水相浊度(OD1)。
自聚集能力/疏水性(%)=(1-OD1/OD0)×100%。
结果如表3所示,融合魏斯氏菌CGMCC No.27139的自聚集能力和疏水性与阳性对照菌LGG相当,说明该菌株具有一定的肠道定植能力。
表3融合魏斯氏菌CGMCC No.27139的自聚集能力和疏水性
实施例3融合魏斯氏菌CGMCC No.27139改善高脂饮食诱导的仓鼠高脂血症
1、融合魏斯氏菌CGMCC No.27139对高脂血症仓鼠模型的干预的实验设计
采用金色叙利亚仓鼠建立高脂血症动物模型,予以融合魏斯氏菌CGMCC No.27139菌悬液灌胃干预。具体实验设计如下:24只8周龄SPF级金色叙利亚仓鼠在25℃、12h光/暗循环的环境下,予以普通啮齿类动物饲料和灭菌水喂养,适应1周后,随机分成3组(N=8),每笼2只,分别为正常对照组(NC组)、高脂模型组(HFD组)和融合魏斯氏菌CGMCC No.27139干预组(Wc1982组)。随后进行干预,NC组给予普通饲料(D.12102),HFD组和Wc1982组给予高脂饲料(D.12108C),同时对NC组和HFD组仓鼠每日灌胃1mL/只PBS,Wc1982组仓鼠每日灌胃1mL/只CGMCC No.27139菌悬液(菌量约5×108CFU),连续灌胃6周。每天检查仓鼠的一般健康状况,每周监测饮用水消耗、食物摄入和体重。实验结束后,检测仓鼠血清的脂质四项、炎症因子、内毒素(ET)、谷丙转氨酶(ALT)和谷草转氨酶(AST)指标,以及肝脏的病理变化,来评价融合魏斯氏菌CGMCCNo.27139对高脂血症模型的预防干预效果。
2、融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的健康状况、体重、能量摄入量和饲料转化率的影响
仓鼠每日活动性及精神状态良好,融合魏斯氏菌CGMCCNo.27139干预对仓鼠无明显毒副作用。融合魏斯氏菌CGMCCNo.27139对高脂血症模型仓鼠体重的影响如表4和图1的A所示,与NC组相比,HFD组仓鼠体重从第2周到第4周显著增加(P<0.05),其他周两组间无显著性差异(P>0.05);Wc1982组仓鼠体重与HFD组相比无显著性差异(P>0.05),说明该菌株对高脂血症模型仓鼠体重没有影响。融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠能量摄入量的影响如表5和图1的B所示,HFD组仓鼠在第1-3周和第6周的能量摄入量及其总能量摄入量显著高于NC组(P<0.05),在第4和5周的能量摄入量高于NC组,但是没有统计学意义(P>0.05);Wc1982组仓鼠能量摄入量与HFD组相比无显著性差异(P>0.05)。融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠饲料转化率的影响如表6所示,从喂食第2周起,三组间饲料转化率无显著性差异(P>0.05),说明三组仓鼠在摄入相同的能量时,体重增加无明显差异。
表4每周每只仓鼠平均体重统计表(g)
注:与HFD组相比,*,P<0.05。
表5每周每笼仓鼠平均能量摄入量及总能量摄入量统计表(kcal)
注:与HFD组相比,*,P<0.05;**,P<0.01;***,P<0.001。
表6每周每笼仓鼠饲料转化率统计表(g/kcal)
注:与HFD组相比,*,P<0.05。3、融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的血清脂质的影响
结果如表7和图2所示,与NC组相比,HFD组仓鼠血清总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)水平显著升高,高密度脂蛋白胆固醇(HDL-C)水平显著降低(P<0.05);Wc1982组仓鼠血清TC、TG、LDL-C水平显著低于HFD组,HDL-C水平显著高于HFD组(P<0.05),说明融合魏斯氏菌CGMCC No.27139具有降低血脂的功效。
表7仓鼠血清脂质浓度(mmol/L)
注:与HFD组相比,***,P<0.001。
4、融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的血清炎症因子和血清内毒素(ET)的影响
结果如表8和图3所示,与NC组相比,HFD组仓鼠血清白介素-1β(IL-1β)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、单核细胞趋化蛋白-1(MCP-1)和内毒素(ET)的水平显著升高(P<0.05);与HFD组相比,Wc1982组仓鼠血清IL-1β、IL-6、TNF-α、MCP-1和ET的水平显著降低(P<0.05)。上述结果表明,融合魏斯氏菌CGMCCNo.27139具有降低血清炎症因子和ET的作用。
表8仓鼠血清炎症因子和内毒素浓度(pg/mL)
注:与HFD组相比,*,P<0.05;**,P<0.01;***,P<0.001。
5、融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠的肝脏的影响
融合魏斯氏菌CGMCC No.27139对高脂血症模型仓鼠血清谷丙转氨酶(ALT)和谷草转氨酶(AST)的影响如表9和图4所示,HFD组仓鼠血清ALT和AST水平与NC组相比显著升高(P<0.05);Wc1982组仓鼠血清ALT和AST水平显著低于HFD组(P<0.05)。同时肝脏组织镜下观察(图5)表明,NC组仓鼠肝脏细胞形态正常,排列整齐,无脂肪变性及气球样变。HFD组仓鼠肝脏细胞排列无序,体积增大,可见弥漫性肝细胞脂肪变性,胞质中出现泡沫状微小脂滴(实心箭头);并可见肝细胞气球样变性,胞质疏松淡染(线型箭头);肝小叶内可见散在肝细胞小灶性坏死伴淋巴细胞浸润(开叉箭头);肝血窦周围可见纤维组织增生。与HFD组相比,Wc1982组仓鼠显示出较轻的病理症状,肝细胞形态改善,细胞排列较整齐,脂肪变性程度较轻;炎症反应较轻,肝细胞气球样变性减少,肝小叶内可见少量肝细胞点状坏死伴淋巴细胞浸润。
上述结果表明,融合魏斯氏菌CGMCC No.27139具有显著降低血清ALT和AST的作用,同时可改善由高脂饮食导致的肝损伤,具有保护肝脏功能的功效。
表9仓鼠血清谷丙转氨酶和谷草转氨酶浓度(ng/mL)
注:与HFD组相比,*,P<0.05;***,P<0.001。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.融合魏斯氏菌(Weissella confusa)Wc1982,其特征在于,其保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.27139。
2.一种菌剂,其特征在于,所述菌剂包含权利要求1所述的融合魏斯氏菌(Weissellaconfusa)Wc1982。
3.权利要求2所述的菌剂的制备方法,其特征在于,所述方法包括培养所述融合魏斯氏菌(Weissella confusa)Wc1982的步骤。
4.根据权利要求3所述的制备方法,其特征在于,所述培养使用的培养基为MRS培养基。
5.根据权利要求3或4所述的制备方法,其特征在于,所述培养在35-37℃条件下进行。
6.权利要求1所述的融合魏斯氏菌(Weissella confusa)Wc1982或权利要求2所述的菌剂在制备食品或药物中的应用。
7.权利要求1所述的融合魏斯氏菌(Weissella confusa)Wc1982或权利要求2所述的菌剂在制备用于预防、改善或治疗高脂血症的产品中的应用。
8.权利要求1所述的融合魏斯氏菌(Weissella confusa)Wc1982或权利要求2所述的菌剂在制备用于降低炎症因子和/或内毒素水平的产品中的应用。
9.权利要求1所述的融合魏斯氏菌(Weissella confusa)Wc1982或权利要求2所述的菌剂在制备用于预防、缓解或治疗因脂代谢紊乱导致的肝脏疾病的产品中的应用。
10.一种产品,其特征在于,所述产品包含权利要求1所述的融合魏斯氏菌(Weissellaconfusa)Wc1982或权利要求2所述的菌剂,或者,所述产品由权利要求1所述的融合魏斯氏菌(Weissella confusa)Wc1982制备得到。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311096261.3A CN117264812A (zh) | 2023-08-29 | 2023-08-29 | 一株融合魏斯氏菌及其在制备降脂产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311096261.3A CN117264812A (zh) | 2023-08-29 | 2023-08-29 | 一株融合魏斯氏菌及其在制备降脂产品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117264812A true CN117264812A (zh) | 2023-12-22 |
Family
ID=89209531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311096261.3A Pending CN117264812A (zh) | 2023-08-29 | 2023-08-29 | 一株融合魏斯氏菌及其在制备降脂产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117264812A (zh) |
-
2023
- 2023-08-29 CN CN202311096261.3A patent/CN117264812A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111534446B (zh) | 罗伊氏乳杆菌及其应用 | |
CN112358999B (zh) | 一种罗伊氏乳杆菌及其应用 | |
CN106282072B (zh) | 一种复合乳酸菌微生态制剂及其制备方法与应用 | |
CN112011481B (zh) | 一株防治畜禽细菌性腹泻的罗伊氏乳杆菌及其应用 | |
CN113293113B (zh) | 一株长双歧杆菌mi-186及其应用 | |
CN113234640B (zh) | 一株长双歧杆菌mf-269及其应用 | |
CN109055268B (zh) | 一种复合微生态制剂及其在蜜蜂养殖过程中的应用 | |
CN111534447B (zh) | 约氏乳杆菌及其应用 | |
CN106434411B (zh) | 一种大熊猫源植物乳酸杆菌及应用 | |
CN114085789B (zh) | 戊糖片球菌ma.wtpqj01及其应用 | |
CN114806978B (zh) | 约氏乳杆菌sxdt-23及其应用 | |
CN112574924B (zh) | 一种枯草芽孢杆菌菌株及其微生态制剂和应用 | |
CN113040390B (zh) | 一株益生、耐盐约氏乳杆菌及其在畜禽水产养殖中防治病原菌的应用 | |
CN117143785B (zh) | 一株片球菌及其应用 | |
CN114231470A (zh) | 一株可缓解溃疡性结肠炎的嗜酸乳杆菌及其应用 | |
CN116083325A (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN117683669A (zh) | 一株罗伊氏乳杆菌及其应用 | |
CN115287224A (zh) | 一株改善本源动物肠道微生物发育的牦牛源罗伊氏乳杆菌及其应用 | |
CN113337440B (zh) | 一株唾液乳杆菌mg-587及其应用 | |
CN114854638A (zh) | 一株高效表达腺苷脱氨酶缓解结肠炎副干酪乳杆菌 | |
CN113088468B (zh) | 干酪乳杆菌Ma.GLRGJ 1及其应用 | |
CN117143767B (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN115651860A (zh) | 凝结芽孢杆菌bc-hyc株及其应用 | |
CN117264812A (zh) | 一株融合魏斯氏菌及其在制备降脂产品中的应用 | |
CN115433700B (zh) | 一株沙氏别样杆菌及其在制备防治炎症性肠病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |